Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654758 | 0.98 | HPGD (0.44) | HPGDUSP2SMN1; SMN2CTSKPREP | |
| SCHEMBL2125387 | 0.94 | USP2 (0.42) | HPGDUSP2SMN1; SMN2CTSKPREP | |
| SCHEMBL23913543 | 0.86 | MMP3 (0.35) | HPGDMMP3 | |
| SCHEMBL28306165 | 0.84 | USP2 (0.46) | HPGDUSP2SMN1; SMN2CTSKPREP | |
| SCHEMBL13100991 | 0.84 | USP2 (0.40) | HPGDUSP2SMN1; SMN2CTSKPREP | |
| SCHEMBL30620183 | 0.82 | HPGD (0.45) | HPGDUSP2SMN1; SMN2CTSKPREP | |
| SCHEMBL13101489 | 0.79 | USP2 (0.39) | HPGDUSP2SMN1; SMN2CTSKEPHX1 | |
| SCHEMBL13101487 | 0.79 | USP2 (0.50) | HPGDUSP2SMN1; SMN2EPHX1MAPK1 | |
| SCHEMBL11368635 | 0.79 | MMP3 (0.42) | HPGDUSP2SMN1; SMN2MAPK1MMP3 | |
| SCHEMBL23913166 | 0.78 | MMP3 (0.31) | MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4612140-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2025-09-10 | — | — | EP | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-01-09 | — | — | US | disclosed |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024254404-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-119101070-A | Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-113683614-B | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-1090612-C | Amine derivatives of oxo-and hydroxy-substituted hydrocarbons | NARHEX LTD (HK) | 2002-09-11 | — | — | CN | disclosed |
| US-6258806-B1 | PEPTIDES WITH CYCLIC DIAZAALKANES FOR PREVENTION OF PREMATURE METABOLISM METHOD FOR INHIBITING AN HIV PROTEASE IN A MAMMAL IN NEED OF SUCH PROTEASE INHIBITION, COMPRISING ADMINISTERING TO SAID MAMMAL AN EFFECTIVE DOSAGE | NARHEX LIMITED (HK) | 2001-07-10 | — | — | US | disclosed |
| US-6069163-A | SUBSTITUTED AZAPEPEPTIDE ACIDS ARE SUITABLE FOR USE IN THE TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS | MERCK & CO., INC. (US) | 2000-05-30 | — | — | US | disclosed |
| US-5942504-A | INHIBITORS OF RETROVIRAL PROTEASES; TREATMENT OF AIDS AND HIV | NARHEX LIMITED (HK) | 1999-08-24 | — | — | US | disclosed |
| WO-1999020272-A1 | AZAPEPTIDE ACIDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5679688-A | RETROVIRAL PROTEASE INHIBITORS; AIDS THERAPY | NARHEX LIMITED (HK) | 1997-10-21 | — | — | US | disclosed |
| CN-1100090-A | amine derivatives of oxo-and hydroxy-substituted hydrocarbons | NARHEX LTD (HK) | 1995-03-15 | — | — | CN | disclosed |
| EP-0633881-A4 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS. | — | 1995-02-22 | — | — | EP | disclosed |
| EP-0633881-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | Narhex Limited (HK) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993018006-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LIMITED (HK) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | HPGD 1315/4885USP2 2003/4885SMN1; SMN2 2895/4885 |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, ZC3HAV1L, CUL1 | HPGD 3358/4885USP2 3222/4885SMN1; SMN2 773/4885 |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | KRAS, NRAS, HRAS | HPGD 215/4885USP2 3680/4885SMN1; SMN2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.